Article

Verteporfin-maker QLT to merge with Atrix

Vancouver, British Columbia-An $855 million deal will unite verteporfin (Visudyne) developer QLT Inc. and Atrix Laboratories Inc. to build QLT's business and accelerate strategic initiatives.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
Kodiak announces new data from APEX study of KSI-101
September 16th 2025

Kodiak announces new data from APEX study of KSI-101

3 Things You Should Know About the GA Pipeline
September 16th 2025

NK Insights: An Interactive Corneal Sensitivity Testing Workshop

Time and motion studies demonstrate workflow efficiencies of Alcon’s Unity VCS in cataract and vitreoretinal surgery
September 16th 2025

Time and motion studies demonstrate workflow efficiencies of Alcon’s Unity VCS in cataract and vitreoretinal surgery

3 Things You Should Know About the GA Pipeline
September 16th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Q&A: Sofia Androudi on retinal disorders mimicking inherited retinal diseases
September 16th 2025

Q&A: Sofia Androudi on retinal disorders mimicking inherited retinal diseases

Belite Bio concludes phase 3 DRAGON study for Stargardt disease
September 16th 2025

Belite Bio concludes phase 3 DRAGON study for Stargardt disease

© 2025 MJH Life Sciences

All rights reserved.